04-05-2005, 09:16 PM
|
 |
Registered User
|
|
Join Date: Mar 2005
Posts: 199
Thanks: 0
Thanked 4 Times in 4 Posts
|
|
|
Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin
Journal:
1: Br J Haematol. 2003 Oct;123(1):103-5.
Full Text Article:
http://tinyurl.com/4djbx
Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.
Baron F, Frere P, Fillet G, Beguin Y.
Department of Medicine, Division of Haematology, University of Liege, Liege, Belgium.
We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high-dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9.5 +/- 1.1 g/dl and 12.5 +/- 0.9 g/dl at the first and second transplant respectively (P < 0.001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (P < 0.001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.
PMID: 14510949 [PubMed - indexed for MEDLINE] http://tinyurl.com/5py79
|
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
